Dyne Therapeutics Reported Positive Clinical Trial Results
The company shared one-year data for a new drug targeting the underlying causes of myotonic dystrophy type 1.
Updated on Sept. 29, 2026 in Stroke
Live Poll
Do you trust that pharmaceutical companies are prioritizing effective treatments for rare, chronic genetic diseases?
Dyne Therapeutics has released one-year clinical trial results showing functional improvements in patients with myotonic dystrophy type 1 treated with z-basivarsen. The findings indicate sustained progress across several physical mobility and muscle strength measures.
Why it matters
Z-basivarsen is designed to correct underlying splicing abnormalities in myotonic dystrophy type 1 by reducing toxic nuclear DMPK RNA. This approach aims to address the root biological drivers of a progressive condition currently lacking targeted therapies.
Participants demonstrated a 25.2% improvement on the Myotonic Dystrophy Health Index total score and a 4.8% increase in quantitative muscle testing at 12 months. These results were gathered from a pooled group of 25 to 26 subjects.
The players
Dyne Therapeutics
This biotechnology company based in Waltham, Massachusetts focuses on developing oligonucleotide-based therapies for muscle diseases.
The details
The drug utilizes an antisense oligonucleotide conjugated to an antigen-binding fragment to target transferrin receptors and release splicing proteins. As of April 20, 2026, the treatment demonstrated a favorable safety profile with no serious treatment-related adverse events.
Timeline
April 20, 2026 marked the cutoff date for safety data.
September 29, 2026 was the date results were presented at professional meetings.
Q1 2027 is the expected date for topline data from the registrational expansion cohort.
Q3 2027 is the target window for a potential U.S. Accelerated Approval application.
The Big Picture
This data marks a key one-year progress update for the ongoing ACHIEVE clinical trial program. The results follow a pattern set by recent advances in oligonucleotide-based therapies targeting rare neuromuscular disorders.
These clinical findings suggest potential future treatment options that could eventually improve daily muscle function and physical independence for patients. The drug is currently in development and not yet available for general medical use.
The takeaway
The successful one-year trial data represents a significant milestone for patients living with myotonic dystrophy type 1. Future regulatory milestones will determine if this therapy becomes a viable standard of care for the disease.
What happens next
Dyne Therapeutics expects to release topline data from its registrational expansion cohort in the first quarter of 2027, followed by a planned submission for U.S. Accelerated Approval in the third quarter of 2027.
Further reading
For additional context on related research, visit the Stroke section.
More information
For more information, visit the ACHIEVE clinical trial information portal.
Live Poll
Do you trust that pharmaceutical companies are prioritizing effective treatments for rare, chronic genetic diseases?
